Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. The company is based in New York, New York.
Market Cap | 473.012 Million | Shares Outstanding | 116.505 Million | Avg 30-day Volume | 359.467 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -1.15 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -156.688 Million |
Price to Book Value | 1.2863 | Operating Margin | 0.0 | Enterprise Value | 110.516 Million |
Current Ratio | 11.521 | EPS Growth | 0 | Quick Ratio | 11.367 |
1 Yr BETA | 1.3657 | 52-week High/Low | 11.38 / 3.15 | Profit Margin | 0.0 |
Operating Cash Flow Growth | 0.0 | Altman Z-Score | 7.0491 | Free Cash Flow to Firm | 0 |
Earnings Report | 2022-08-09 |
Please sign in first
none
2 Thousand total shares from 2 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
BUTCHKO JULIA G. CHIEF DEV. & TECH. OFFICER |
|
282,074 | 2022-05-24 | 6 |
SALZMANN PETER CHIEF EXECUTIVE OFFICER |
|
555,635 | 2022-05-24 | 6 |
MACIAS WILLIAM L. CHIEF MEDICAL OFFICER |
|
195,948 | 2022-04-19 | 4 |
LEVINE MARK S. CHIEF LEGAL OFFICER |
|
526,000 | 2022-01-28 | 2 |
|
220,718 | 2022-01-10 | 2 | |
|
276,399 | 2022-01-10 | 2 | |
|
275,899 | 2022-01-10 | 2 | |
|
702,474 | 2022-01-10 | 1 | |
|
289,146 | 2022-01-10 | 2 | |
BARNETT EVA RENEE CHIEF FINANCIAL OFFICER |
|
172,541 | 2022-01-07 | 4 |
|
73,388,664 | 2021-08-02 | 1 | |
JAIN RITA CHIEF MEDICAL OFFICER |
|
471,665 | 2021-03-19 | 0 |
YANCHIK CONNEALY PAMELA CHIEF FINANCIAL OFFICER |
|
208,200 | 2021-03-19 | 0 |
ELLIOTT MICHAEL JAMES CHIEF SCIENTIFIC OFFICER |
|
439,900 | 2021-03-19 | 0 |
WONG RODERICK CHIEF EXECUTIVE OFFICER |
|
902,498 | 2019-12-11 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2022-05-25 16:23:29 -0400 | 2022-05-24 | S | 1,471 | $3.79 | d | 555,635 | direct | 4.9751 | 12.6866 | 12.6866 | 6 | 0.0 | 1 | |||
2022-05-25 16:26:04 -0400 | 2022-05-24 | S | 492 | $3.79 | d | 282,074 | direct | 4.9751 | 12.6866 | 12.6866 | 6 | 0.0 | 1 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
IMMUNOVANT INC IMVT | 2022-06-30 22:15:03 UTC | 1.2095 | 0.3605 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 21:45:03 UTC | 1.2095 | 0.3605 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 21:15:03 UTC | 1.2095 | 0.3605 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 20:45:03 UTC | 1.2095 | 0.3605 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 20:15:04 UTC | 1.2095 | 0.3605 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 19:45:03 UTC | 1.2095 | 0.3605 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 19:15:03 UTC | 1.2095 | 0.3605 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 18:45:04 UTC | 1.2095 | 0.3605 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 18:15:04 UTC | 1.2095 | 0.3605 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 17:45:03 UTC | 1.2095 | 0.3605 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 17:15:03 UTC | 1.2095 | 0.3605 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 16:45:04 UTC | 1.1887 | 0.3813 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 16:15:03 UTC | 1.1887 | 0.3813 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 15:45:03 UTC | 1.1887 | 0.3813 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 15:15:03 UTC | 1.1887 | 0.3813 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 14:45:03 UTC | 1.1887 | 0.3813 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 14:15:03 UTC | 1.1887 | 0.3813 | 1200000 |
IMMUNOVANT INC IMVT | 2022-06-30 13:45:03 UTC | 1.1873 | 0.3827 | 1100000 |
IMMUNOVANT INC IMVT | 2022-06-30 13:15:03 UTC | 1.1873 | 0.3827 | 1100000 |
IMMUNOVANT INC IMVT | 2022-06-30 12:45:03 UTC | 1.1873 | 0.3827 | 1100000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|